You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 14, 2024

Investigational Drug Information for Lenabasum


✉ Email this page to a colleague

« Back to Dashboard


What is the development status for investigational drug Lenabasum?

Lenabasum is an investigational drug.

There have been 6 clinical trials for Lenabasum. The most recent clinical trial was a Phase 2 trial, which was initiated on December 18th 2017.

The most common disease conditions in clinical trials are Dermatomyositis, Fibrosis, and Cystic Fibrosis. The leading clinical trial sponsors are Corbus Pharmaceuticals Inc., Cystic Fibrosis Foundation Therapeutics, and National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS).

There are seven US patents protecting this investigational drug and ninety-two international patents.

Recent Clinical Trials for Lenabasum
TitleSponsorPhase
Trial to Evaluate Efficacy and Safety of Lenabasum in DermatomyositisCorbus Pharmaceuticals Inc.Phase 3
Trial to Evaluate Efficacy and Safety of Lenabasum in Cystic FibrosisCystic Fibrosis FoundationPhase 2
Trial to Evaluate Efficacy and Safety of Lenabasum in Cystic FibrosisCystic Fibrosis Foundation TherapeuticsPhase 2

See all Lenabasum clinical trials

Clinical Trial Summary for Lenabasum

Top disease conditions for Lenabasum
Top clinical trial sponsors for Lenabasum

See all Lenabasum clinical trials

US Patents for Lenabasum

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Lenabasum ⤷  Subscribe Pre-spray emulsions and powders containing non-polar compounds Virun, Inc. (Pomona, CA) ⤷  Subscribe
Lenabasum ⤷  Subscribe Formulations of water-soluble derivatives of vitamin E and soft gel compositions, concentrates and powders containing same Virun, Inc. (Pomona, CA) ⤷  Subscribe
Lenabasum ⤷  Subscribe 4-phenylamino-quinazolin-6-yl-amides Warner-Lambert Company LLC (Morris Plains, NJ) ⤷  Subscribe
Lenabasum ⤷  Subscribe Method for treatment of HIV and diseases of immune dysregulation ⤷  Subscribe
Lenabasum ⤷  Subscribe 4-phenylamino-quinazolin-6-yl-amides Warner-Lambert Company LLC (Morris Plains, NJ) ⤷  Subscribe
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Lenabasum

Drugname Country Document Number Estimated Expiration Related US Patent
Lenabasum Canada CA2961829 2034-09-18 ⤷  Subscribe
Lenabasum European Patent Office EP3193834 2034-09-18 ⤷  Subscribe
Lenabasum World Intellectual Property Organization (WIPO) WO2016044805 2034-09-18 ⤷  Subscribe
Lenabasum World Intellectual Property Organization (WIPO) WO2016044813 2034-09-18 ⤷  Subscribe
Lenabasum Canada CA2961829 2034-09-18 ⤷  Subscribe
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.